Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Momelotinib→

Momelotinib Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
1056634-68-4
Molecular formula
C23H22N6O2
Molecular weight
414.5 g/mol
Drug class
Janus kinase 1/2 and activin A receptor type 1 (ACVR1/ALK2) inhibitortargeted myelofibrosis therapy
Mechanism of action
Inhibits wild-type JAK1 and JAK2 and mutant JAK2 V617F, reducing cytokine-driven JAK-STAT signalling. It also inhibits ACVR1/ALK2, reducing hepcidin expression and increasing iron availability for erythropoiesis, which is relevant to its effect on anaemia.
Indications / reported uses
  • Treatment of adults with intermediate- or high-risk myelofibrosis, including primary myelofibrosis and secondary myelofibrosis after polycythaemia vera or essential thrombocythaemia, in patients with anaemia

Sources: US DailyMed — OJJAARA (momelotinib), updated 13 May 2026 · US FDA prescribing information · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Momelotinib Environmental Risk Assessment (ERA) (the Momelotinib ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.